Matthew P Smeltzer1, Chun Chieh Lin2, Feng-Ming Spring Kong3, Ahmedin Jemal2, Raymond U Osarogiagbon4. 1. School of Public Health, University of Memphis, Memphis, Tenn. 2. American Cancer Society, Inc, Atlanta, Ga. 3. Department of Radiation Oncology, IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Ind. 4. Thoracic Oncology Research Group, Baptist Cancer Center, Memphis, Tenn. Electronic address: rosarogi@bmhcc.org.
Abstract
OBJECTIVE: Unlike complete (R0) resection guidelines, current National Comprehensive Cancer Network (NCCN) adjuvant therapy guidelines after incomplete (R1/R2) resection of non-small cell lung cancer (NSCLC) are based on low-level evidence. We attempted to validate them. METHODS: Patients with pathologic stage I-IIIA NSCLC from 2004 to 2011 in the National Cancer Database were stratified by margin status, NCCN-specified stage groupings, and adjuvant therapy exposure (none, radiotherapy, chemotherapy, or both). Five-year overall survival (OS) and hazard ratios, adjusted for patient and institutional characteristics, were compared. We used a parallel analysis of R0 resections to validate our methodology. RESULTS: We analyzed 3461 R1/R2, and 78,979 R0 resections. After R0 resection, the NCCN-recommended option was associated with the best survival across all stage groups, supporting our analytic approach. Patients with R1/R2 stage IA treated with radiation had a 26% OS, compared with 58% with no treatment (P = .003). In patients with stage IB/IIA(N0) R1/R2, radiation was associated with a 25% OS compared with 47% with no treatment (P = .025) and 62% with chemotherapy (P < .007). Chemoradiation was not associated with a survival benefit in either group. Patients with IIA(N1)/IIB and IIIA had better survival with chemotherapy or chemoradiation. No group had a survival benefit with radiation alone. CONCLUSIONS: NCCN adjuvant therapy guidelines after complete resection, based on high-level evidence, are validated, but not guidelines for patients with incompletely resected early-stage NSCLC, which are based on low-level evidence. Monomodality postoperative radiotherapy was not validated for any stage. Specific studies are needed to determine optimal management after incomplete resection.
OBJECTIVE: Unlike complete (R0) resection guidelines, current National Comprehensive Cancer Network (NCCN) adjuvant therapy guidelines after incomplete (R1/R2) resection of non-small cell lung cancer (NSCLC) are based on low-level evidence. We attempted to validate them. METHODS:Patients with pathologic stage I-IIIA NSCLC from 2004 to 2011 in the National Cancer Database were stratified by margin status, NCCN-specified stage groupings, and adjuvant therapy exposure (none, radiotherapy, chemotherapy, or both). Five-year overall survival (OS) and hazard ratios, adjusted for patient and institutional characteristics, were compared. We used a parallel analysis of R0 resections to validate our methodology. RESULTS: We analyzed 3461 R1/R2, and 78,979 R0 resections. After R0 resection, the NCCN-recommended option was associated with the best survival across all stage groups, supporting our analytic approach. Patients with R1/R2 stage IA treated with radiation had a 26% OS, compared with 58% with no treatment (P = .003). In patients with stage IB/IIA(N0) R1/R2, radiation was associated with a 25% OS compared with 47% with no treatment (P = .025) and 62% with chemotherapy (P < .007). Chemoradiation was not associated with a survival benefit in either group. Patients with IIA(N1)/IIB and IIIA had better survival with chemotherapy or chemoradiation. No group had a survival benefit with radiation alone. CONCLUSIONS: NCCN adjuvant therapy guidelines after complete resection, based on high-level evidence, are validated, but not guidelines for patients with incompletely resected early-stage NSCLC, which are based on low-level evidence. Monomodality postoperative radiotherapy was not validated for any stage. Specific studies are needed to determine optimal management after incomplete resection.
Authors: S M Keller; S Adak; H Wagner; A Herskovic; R Komaki; B J Brooks; M C Perry; R B Livingston; D H Johnson Journal: N Engl J Med Date: 2000-10-26 Impact factor: 91.245
Authors: Alex G Little; Valerie W Rusch; James A Bonner; Laurie E Gaspar; Mark R Green; W Richard Webb; Andrew K Stewart Journal: Ann Thorac Surg Date: 2005-12 Impact factor: 4.330
Authors: Jacquelyn G Hancock; Joshua E Rosen; Alberto Antonicelli; Amy Moreno; Anthony W Kim; Frank C Detterbeck; Daniel J Boffa Journal: Ann Thorac Surg Date: 2014-12-17 Impact factor: 4.330
Authors: Brian E Lally; Daniel Zelterman; Joseph M Colasanto; Bruce G Haffty; Frank C Detterbeck; Lynn D Wilson Journal: J Clin Oncol Date: 2006-06-12 Impact factor: 44.544
Authors: Joachim Pfannschmidt; Thomas Muley; Heinrich Bülzebruck; Hans Hoffmann; Hendrik Dienemann Journal: Lung Cancer Date: 2006-11-22 Impact factor: 5.705
Authors: Charles A Butts; Keyue Ding; Lesley Seymour; Philip Twumasi-Ankrah; Barbara Graham; David Gandara; David H Johnson; Kenneth A Kesler; Mark Green; Mark Vincent; Yvon Cormier; Glenwood Goss; Brian Findlay; Michael Johnston; Ming-Sound Tsao; Frances A Shepherd Journal: J Clin Oncol Date: 2009-11-23 Impact factor: 44.544
Authors: Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: Vignesh Raman; Oliver K Jawitz; Chi-Fu J Yang; Soraya L Voigt; Anthony W Kim; Betty C Tong; Thomas A D'Amico; David H Harpole Journal: J Thorac Cardiovasc Surg Date: 2019-09-30 Impact factor: 5.209
Authors: Matthew P Smeltzer; Nicholas R Faris; Meredith A Ray; Carrie Fehnel; Cheryl Houston-Harris; Philip Ojeabulu; Olawale Akinbobola; Yu-Sheng Lee; Meghan Meadows; R Samuel Signore; Lynn Wiggins; David Talton; Edmond Owen; Lawrence E Deese; Richard Eubanks; Bradley A Wolf; Paul Levy; E Todd Robbins; Raymond U Osarogiagbon Journal: Ann Thorac Surg Date: 2018-12-27 Impact factor: 4.330
Authors: Dustin K Lieu; Li Ding; Elizabeth A David; Sean C Wightman; Scott M Atay; P Michael McFadden; Anthony W Kim Journal: J Thorac Dis Date: 2021-05 Impact factor: 3.005
Authors: Mitchell S von Itzstein; Rong Lu; Kemp H Kernstine; Ethan A Halm; Shidan Wang; Yang Xie; David E Gerber Journal: Cancer Med Date: 2020-04-21 Impact factor: 4.452
Authors: Ziqing Zeng; Bo Yan; Yulong Chen; Lianmin Zhang; Jianquan Zhu; Fan Yang; Feng Wei; Terence Chi Chun Tam; Diego Kauffmann-Guerrero; Ross Andrew Soo; Xiubao Ren; Jian You Journal: Transl Lung Cancer Res Date: 2020-12
Authors: Matthew P Smeltzer; Nicholas R Faris; Carrie Fehnel; Olawale Akinbobola; Andrea Saulsberry; Meghan Meadows-Taylor; Alicia Pacheco; Meredith Ray; Raymond U Osarogiagbon Journal: JTO Clin Res Rep Date: 2021-03-09
Authors: Matthew P Smeltzer; Yu-Sheng Lee; Nicholas R Faris M Div; Carrie Fehnel; Olawale Akinbobola; Meghan Meadows-Taylor; David Spencer; Elizabeth Sales; Sherry Okun; Christopher Giampapa; Amal Anga; Alicia Pacheco; Meredith A Ray; Raymond U Osarogiagbon Journal: J Thorac Oncol Date: 2021-07-16 Impact factor: 20.121